Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 2912345...1020...Last »

R&D Cooperation Between China and Western Pharma Companies Up 70 Percent

China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.

Read More »

Half of Europe’s clinical trials fail to report results

Almost half of all European-registered clinical trials have breached EU rules by failing to report results, according to a published analysis.

Read More »

Vital Therapies shares dive as liver system fails trial

Vital Therapies Inc. will explore strategic options after the U.S. biotech firm’s liver disease treatment failed to meet the main goal of a late-stage study, driving its shares down more than 70 percent.

Read More »

Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial

Bristol-Myers Squibb’s experimental drug BMS-986165 helped reduce the severity of the most common form of psoriasis in a mid-stage trial.

Read More »

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd.’s lead drug for treating moderate-to-severe acne met the main goals of the company’s third late-stage study, sending its shares up 57 percent in extended trading.

Read More »

Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference

Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).

Read More »

EpicGenetics and Massachusetts General Hospital to Launch Fibromyalgia Clinical Trial

EpicGenetics and Massachusetts General Hospital are launching a Phase II clinical trial to test a tuberculosis vaccine, CBG, as a potential treatment for fibromyalgia.

Read More »

Merck KGaA, Pfizer’s immuno-drug shown to alleviate kidney cancer

Merck KGaA said the immunotherapy Bavencio, jointly developed with Pfizer Inc., delayed the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.

Read More »

Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz and Tremfya in Patients with Moderate-to-Severe Plaque Psoriasis

Eli Lilly and Company announced today the initiation of the IXORA-R head-to-head clinical trial, designed to evaluate superiority between Taltz (ixekizumab) and Tremfya (guselkumab) in adult patients with moderate-to-severe plaque psoriasis.

Read More »

Consort, Opiant to develop nasal spray for opioid overdose treatment

Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

Read More »

Tezepelumab Granted Breakthrough Therapy By FDA

Amgen and AstraZeneca announced that the U.S. FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.

Read More »

With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos’ Filgotinib Inches Toward Approval

Gilead Sciences Inc. and its partner Galapagos NV announced results from the Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis.

Read More »

Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Pfizer

Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.

Read More »

ProQR childhood blindness drug succeeds in early study

An interim analysis of an early-stage trial showed that ProQR Therapeutics NV’s experimental treatment for a rare form of childhood blindness improved vision.

Read More »

Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John McCain

Citing the National Institutes of Health (NIH), CNN reported there are 274 glioblastoma multiforme studies underway or recruiting across the United States.

Read More »

Esperion’s Bemopedoic Acid Treatments Hit the Mark in Two Studies

Ann Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.

Read More »

Pfizer rare heart disease drug reduces risk of death by 30 percent in study

Pfizer Inc.’s tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug.

Read More »

Bayer, J&J’s bid to widen use of Xarelto hits snag

Bayer and Johnson & Johnson’s campaign to widen the patient group for the companies’ heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.

Read More »

A Glimpse into the Pancreatic Cancer Pipeline

The passing of singing great Aretha Franklin has focused attention on pancreatic cancer. Franklin, 76, succumbed to a neuroendocrine tumor of the pancreas. According to the National Cancer Institute, pancreatic cancer is relatively rare with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases.

Read More »

AstraZeneca inhaler lags GSK drug in lung disease trial

A new AstraZeneca inhaler for chronic lung disease proved worse than a rival GlaxoSmithKline product in a clinical trial.

Read More »

Page 1 of 2912345...1020...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom